VitaSpring Biomedical Co. Ltd. (VSBC) stock
VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31
$0.03+0.00 (0.00%)
Close on Oct 19, 2026Market cap $6.58MP/E –Yield –
VitaSpring Biomedical operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
VitaSpring Biomedical's operating income for the twelve months ending Jul 31, 2026 was -$454.86K. For fiscal 2026 it was -$385.41K. The highest annual figure on record is $1.13M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | -$385.41K | – |
| FY2025 | Jan 31, 2025 | -$679.91K | – |
| FY2024 | Jan 31, 2024 | -$1.12M | – |
| FY2023 | Jan 31, 2023 | -$4.18M | -470.8% |
| FY2022 | Jan 31, 2022 | $1.13M | +164.9% |
| FY2021 | Jan 31, 2021 | $425.38K | +6048.0% |
| FY2020 | Jan 31, 2020 | $6.92K | – |
| FY2019 | Jan 31, 2019 | -$22.40K | – |
| FY2018 | Jan 31, 2018 | -$6.37K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ2 2026 | Jul 31, 2026 | -$161.82K | – |
| Q1 FY2027CQ1 2026 | Apr 30, 2026 | -$75.84K | – |
| Q4 FY2026CQ4 2025 | Jan 31, 2026 | -$81.46K | – |
| Q3 FY2026CQ3 2025 | Oct 31, 2025 | -$135.73K | – |
| Q2 FY2026CQ2 2025 | Jul 31, 2025 | -$99.07K | – |
| Q1 FY2026CQ1 2025 | Apr 30, 2025 | -$69.15K | – |
| Q4 FY2025CQ4 2024 | Jan 31, 2025 | -$126.49K | – |
| Q3 FY2025CQ3 2024 | Oct 31, 2024 | -$117.93K | – |
| Q2 FY2025CQ2 2024 | Jul 31, 2024 | -$218.66K | – |
| Q1 FY2025CQ1 2024 | Apr 30, 2024 | -$216.83K | – |
| Q4 FY2024CQ4 2023 | Jan 31, 2024 | -$225.40K | – |
| Q3 FY2024CQ3 2023 | Oct 31, 2023 | -$234.98K | – |
| Q2 FY2024CQ2 2023 | Jul 31, 2023 | -$353.58K | – |
| Q1 FY2024CQ1 2023 | Apr 30, 2023 | -$304.60K | -188.8% |
| Q4 FY2023CQ4 2022 | Jan 31, 2023 | -$4.16M | -393.3% |
| Q3 FY2023CQ3 2022 | Oct 31, 2022 | -$183.22K | -233.3% |
| Q2 FY2023CQ2 2022 | Jul 31, 2022 | -$174.51K | -169.6% |
| Q1 FY2023CQ1 2022 | Apr 30, 2022 | $343.13K | +91.3% |
| Q4 FY2022CQ4 2021 | Jan 31, 2022 | $1.42M | +151.0% |
| Q3 FY2022CQ3 2021 | Oct 31, 2021 | $137.45K | – |
| Q2 FY2022CQ2 2021 | Jul 31, 2021 | $250.88K | – |
| Q1 FY2022CQ1 2021 | Apr 30, 2021 | $179.41K | – |
| Q4 FY2021CQ4 2020 | Jan 31, 2021 | $565.53K | – |
| Q3 FY2021CQ3 2020 | Oct 31, 2020 | -$31.79K | -163.0% |
| Q2 FY2021CQ2 2020 | Jul 31, 2020 | -$90.62K | – |
| Q1 FY2021CQ1 2020 | Apr 30, 2020 | -$17.75K | – |
| Q4 FY2020CQ4 2019 | Jan 31, 2020 | -$35.79K | -818.8% |
| Q3 FY2020CQ3 2019 | Oct 31, 2019 | $50.45K | – |
| Q2 FY2020CQ2 2019 | Jul 31, 2019 | -$6.15K | – |
| Q1 FY2020CQ1 2019 | Apr 30, 2019 | -$8.51K | – |
| Q1 FY2019CQ1 2018 | Apr 30, 2018 | $4.98K | – |
See a number that looks wrong?